Table 2.
MetS among psychotic-treated and treatment-naïve studied subjects.
| Variables | Total | Psychotic-treated | Treatment-naïve | ||
|---|---|---|---|---|---|
| n=348 | n=236 | n=112 | cOR (95% CI) | p-value | |
| Met / NCEP/ATP III | |||||
| 0 | 75(21.6) | 26(11.0) | 49(43.8) | 1 | |
| 1 | 136(39.1) | 93(39.4) | 43(38.4) | 4.1(2.2-7.4) | 0.0013 |
| 2 | 88(25.2) | 75(31.8) | 13(11.6) | 10.9(5.1-23.2) | <0.0001 |
| ≥3 | 49(14.1) | 42(17.8) | 7(6.2) | 11.3(4.5-47.6) | 0.0001 |
| Met / IDF | |||||
| 0 | 47(13.5) | 16(6.7) | 31(27.7) | 1 | |
| 1 | 123(35.3) | 71(30.3) | 52(46.4) | 2.7(1.3 -5.3) | 0.006 |
| 2 | 96(27.6) | 78(32.7) | 18(16.1) | 8.4(3.8-18.5) | <0.0001 |
| ≥3 | 82(23.6) | 71(30.3) | 11(9.8) | 12.5(5.2-30.0) | <0.0001 |
| Met / WHO | |||||
| 0 | 65(18.7) | 20(8.5) | 45(40.2) | 1 | |
| 1 | 122(35.1) | 75(31.8) | 47(42.0) | 3.6(1.9-6.8) | <0.0001 |
| 2 | 90(25.9) | 79(33.5) | 11(9.8) | 16.2(7.1-36.8) | <0.0001 |
| ≥3 | 71(20.4) | 62(26.2) | 9(8.0) | 15.5(6.5-37.2) | <0.0001 |
NCEP ATP III: National Cholesterol Education Program, Adult Treatment Panel III; IDF: International Diabetes Federation; WHO: World Health Organization; MetS: metabolic syndrome; cOR: crude odds ratio; CI: confidence interval.